Aaron Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$589K Sell
944
-158
-14% -$108K 0.03% 375
2026
Q1
$851K Buy
1,102
+16
+1% +$12.2K 0.05% 255
2025
Q4
$838K Buy
1,086
+288
+36% +$196K 0.05% 288
2025
Q3
$449K Buy
+798
New +$451K 0.03% 437
2025
Q1
Sell
-357
Closed -$254K 486
2024
Q4
$254K Sell
357
-103
-22% -$86.4K 0.03% 361
2024
Q3
$484K Buy
460
+57
+14% +$63.4K 0.06% 195
2024
Q2
$424K Buy
403
+168
+71% +$163K 0.06% 181
2024
Q1
$226K Buy
+235
New +$223K 0.03% 270
2023
Q2
Sell
-248
Closed -$204K 264
2023
Q1
$204K Buy
+248
New +$187K 0.03% 242
2022
Q2
Sell
-127
Closed -$88.7K 692
2022
Q1
$88.7K Buy
+127
New +$80.3K 0.02% 295

Other funds holding REGN

Aaron Wealth Advisors's REGN Position: Q2 2026 in Review

Aaron Wealth Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 14% in Q2 2026, selling an estimated $108K and leaving 944 shares worth $589K. The position accounts for 0.03% of the portfolio, ranked #375.

Aaron Wealth Advisors first reported a position in REGN in Q1 2022 and has held it in 10 quarters since. The position peaked at $851K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Aaron Wealth Advisors held 944 shares of Regeneron Pharmaceuticals worth $589K as of Q2 2026.
  • Aaron Wealth Advisors sold 158 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $108K.
  • Regeneron Pharmaceuticals made up 0.03% of Aaron Wealth Advisors's portfolio in Q2 2026, its #375 holding.
  • Aaron Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
  • Aaron Wealth Advisors's Regeneron Pharmaceuticals position peaked at $851K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Aaron Wealth Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.